Semi-Solid Dosage CDMO Market Size & Growth Forecast 2026–2035, By Segments (Route of Administration, End Use, Product, Service), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Semi-Solid Dosage CDMO Market size stood at USD 37.47 Billion in 2025 and is predicted to grow at a 11.8% CAGR from 2026 to 2035, crossing USD 114.31 Billion by 2035. The industry revenue for 2026 is calculated at USD 41.41 billion.
Get more details on this report
Request Free Sample ReportSemi-Solid Dosage CDMO Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 43.85% share due to established outsourcing base, strong regulatory systems, concentration of pharmaceutical developers, and advanced semi-solid formulation and scale-up expertise.
- Asia Pacific is expanding at 13.22% CAGR, driven by cost-competitive outsourcing, capacity buildout, flexible manufacturing demand, and strengthening technical capabilities of regional CDMOs and infrastructure.
Segment Momentum
- Topical accounted for 84.1% of the market in 2025, supported by widespread use of creams, gels, and ointments, mature formulation processes, scalable manufacturing, and consistent outsourcing demand from clients.
- Biopharmaceutical companies are growing fastest as they seek flexible outsourcing for complex semi-solid formulations, allowing product development to advance without significant in-house manufacturing investment.
Market Expansion Drivers
- Growing prevalence of skin disorders increasing outsourcing demand for topical formulation manufacturing.
- Rising pharmaceutical R&D investments accelerating development of complex semi-solid drug formulations.
- Strategic partnerships between pharma companies and CDMOs expanding specialized production capabilities.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Prominent players in the semi-solid dosage CDMO market include Piramal Pharma Solutions (India), Bora Pharmaceuticals Co., Ltd. (Taiwan), Cambrex Corporation (United States), Pierre Fabre Group (France), Ascendia Pharmaceuticals, Inc. (United States), DPT Laboratories, Ltd. (United States), LGM Pharma, LLC (United States), Pace Analytical Life Sciences, LLC (United States), Catalent, Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As the incidence of dermatological conditions rises, drug developers are expanding portfolios of creams, gels, ointments, and lotions to address both prescription and over-the-counter treatment needs, which is increasing demand for the semi-solid dosage CDMO market. Many pharmaceutical companies do not maintain dedicated semi-solid manufacturing lines because topical products require distinct formulation expertise, contamination control, viscosity management, and packaging compatibility capabilities that differ from oral solids or injectables. This pushes sponsors toward outsourcing partners that can move products from development to commercial production without requiring internal capital investment, reinforcing market demand for CDMOs with established topical formulation and fill-finish infrastructure.
Rising pharmaceutical R&D investments accelerating development of complex semi-solid drug formulations
Higher pharmaceutical R&D spending is translating into a broader pipeline of semi-solid therapies that involve more technically demanding formulations, including products designed for controlled release, improved skin penetration, and better stability, supporting market expansion for the semi-solid dosage CDMO market. As formulation complexity increases, in-house manufacturing becomes less attractive because scale-up, analytical method development, excipient selection, and batch reproducibility require specialized know-how and equipment. CDMOs become central to development programs by helping sponsors shorten formulation cycles and manage technical risk, which is increasing market penetration among small innovators and larger pharmaceutical companies seeking flexible external expertise.
Strategic partnerships between pharma companies and CDMOs expanding specialized production capabilities
Partnerships between pharmaceutical companies and service providers are reshaping capacity decisions in the semi-solid dosage CDMO market by directing investment toward specialized lines for topical and transdermal products, high-containment handling, and tailored packaging formats. These agreements often go beyond transactional manufacturing, giving CDMOs clearer visibility into future demand and enough confidence to expand formulation, scale-up, and commercial production capabilities around sponsor requirements. That deeper integration influences market adoption by making outsourced semi-solid manufacturing more reliable for complex product launches, lifecycle extensions, and multi-product supply strategies.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growing prevalence of skin disorders increasing outsourcing demand for topical formulation manufacturing | 1.90% | High | North America, Europe | High | Near Term |
| Rising pharmaceutical R&D investments accelerating development of complex semi-solid drug formulations | 1.70% | Moderate | North America, Asia Pacific | Medium | Mid Term |
| Strategic partnerships between pharma companies and CDMOs expanding specialized production capabilities | 1.50% | Moderate | Europe, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 43.85% share of the semi-solid dosage CDMO market in 2025, backed by its established outsourced manufacturing base, mature regulatory and quality systems, and strong concentration of pharmaceutical and specialty drug developers. The region’s lead is reinforced by steady demand for contract development and manufacturing of creams, ointments, gels, and other topical formulations, where customers typically prioritize technical formulation expertise, compliant production environments, and reliable scale-up capabilities. This operating environment helps sustain high project flow across development, technology transfer, and commercial manufacturing.
Asia Pacific is projected to expand at a 13.22% CAGR over the forecast period, with growth in the semi-solid dosage CDMO market being propelled by increasing outsourcing to cost-competitive manufacturing locations and the ongoing buildout of formulation and production capabilities across the region. Expansion is being driven in practice by pharmaceutical companies seeking flexible capacity, faster turnaround for product development, and broader supplier options for semi-solid formulations as local CDMOs strengthen technical competencies and manufacturing infrastructure. These adoption patterns are accelerating regional activity across both development-stage and commercial supply programs.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants/Startups i Scale Low Medium High | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Manufacturing Quality ExcellenceGermany emphasizes high-quality semi-solid dosage manufacturing supported by rigorous production standards and advanced pharmaceutical technologies. German CDMOs continue expanding specialized capabilities that enable efficient scale-up and reliable commercial manufacturing for topical products.
France 🇫🇷
Dermatology Manufacturing ExpertiseFrance maintains a strong focus on semi-solid dosage manufacturing for dermatology and topical therapeutic applications. French CDMOs emphasize formulation refinement, production consistency, and regulatory compliance to meet evolving pharmaceutical outsourcing requirements.
Italy 🇮🇹
Flexible Contract ManufacturingItaly strengthens its semi-solid dosage CDMO market through adaptable manufacturing services supporting pharmaceutical companies with varying production volumes. Italian providers prioritize efficient technology transfer, formulation support, and reliable commercial manufacturing for topical dosage forms.
Japan 🇯🇵
Specialized Topical ProductionJapan focuses on technically advanced manufacturing of creams, ointments, and gels requiring consistent formulation performance. Japanese CDMOs strengthen development and production capabilities that address specialized pharmaceutical quality and regulatory expectations for semi-solid dosage products.
South Korea 🇰🇷
Innovation Partnership GrowthSouth Korea expands semi-solid dosage CDMO capabilities through investments in modern manufacturing facilities and collaborative pharmaceutical development. Companies in South Korea increasingly support both domestic and international clients seeking flexible production and formulation expertise.
United States 🇺🇸
Formulation Development StrengthThe U.S. semi-solid dosage CDMO market benefits from strong demand for outsourced formulation development and commercial manufacturing services. CDMOs in the U.S. invest in flexible production capabilities that support topical pharmaceuticals, dermatology products, and complex formulation requirements.
Segment Leadership and Growth Trends
Semi-Solid Dosage CDMO Market Share (%), Route of Administration, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTopical held the dominant position in the semi-solid dosage CDMO market in 2025, accounting for an 84.1% share. This leadership is maintained through the broad and established use of creams, gels, and ointments for dermatology and localized treatment applications, where outsourcing demand remains steady and operational requirements are well defined. In the semi-solid dosage CDMO market, topical products also benefit from mature formulation pathways, scalable manufacturing processes, and consistent client reliance on external partners for development, fill-finish, and regulatory support.
Transdermal is emerging as the fastest-growing route in the semi-solid dosage CDMO market as drug developers seek delivery formats that can improve patient convenience and support controlled systemic absorption. Its momentum is being reinforced by rising interest in differentiated drug delivery approaches that go beyond localized skin treatment and offer extended-release potential. Compared with topical alternatives, transdermal development typically requires more specialized formulation and delivery expertise, which increases the need for CDMO support and strengthens growth in this segment.
End Use Segment Analysis: Pharmaceutical Companies (Largest Segment) vs Biopharmaceutical Companies (Fastest-Growing Segment)
In 2025, pharmaceutical companies represented the largest end-use segment in the semi-solid dosage CDMO market, with a 45.86% share. Their leadership reflects a broad and continuous outsourcing base tied to established semi-solid product portfolios, lifecycle management needs, and routine demand for external manufacturing capacity. The semi-solid dosage CDMO market remains closely aligned with pharmaceutical companies because these firms often manage larger commercial volumes and require dependable partners for formulation optimization, scale-up, and compliant production.
Biopharmaceutical companies are the fastest-growing end-use segment in the semi-solid dosage CDMO market, influenced by expanding interest in more complex and targeted therapies that require specialized delivery and development support. Growth is being reinforced through the need for flexible outsourcing models as these companies advance products through development while avoiding heavy in-house manufacturing investment. Relative to traditional pharmaceutical users, biopharmaceutical companies are creating stronger momentum for CDMOs that can handle technically demanding semi-solid formulations and adapt to evolving pipeline requirements.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Route of Administration | Topical, Transdermal, Others | Topical | Transdermal |
| End Use | Pharmaceutical Companies, Biopharmaceutical Companies, Others | Pharmaceutical Companies | Biopharmaceutical Companies |
| Product | Ointments, Creams and Lotions, Pastes, Gels, Others | Creams and Lotions | Ointments |
| Service | Contract Development, Contract Manufacturing | Contract Manufacturing | Contract Development |
Competitive Landscape and Market Positioning
1. Piramal Pharma Solutions (India)
2. Bora Pharmaceuticals Co. Ltd. (Taiwan)
3. Cambrex Corporation (United States)
4. Pierre Fabre Group (France)
5. Ascendia Pharmaceuticals Inc. (United States)
6. DPT Laboratories Ltd. (United States)
7. LGM Pharma LLC (United States)
8. Pace Analytical Life Sciences LLC (United States)
9. Catalent Inc. (United States)
The semi-solid dosage CDMO market is expanding through increasing demand for specialized topical and transdermal formulations. Contract manufacturers are investing in automated filling technologies, flexible production lines, and formulation optimization capabilities to improve manufacturing efficiency and scalability. Enhanced focus on customized pharmaceutical solutions and quality compliance standards is also driving market competitiveness.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Blue Wolf Capital Partners | Sep-24 | Blue Wolf Capital Partners completed the acquisition of seven European manufacturing facilities from Recipharm. These sites, located in Sweden, France, and Spain, specialize in the development and production of oral solid, semi-solid, and liquid dosage forms. This acquisition forms the cornerstone of a new independent CDMO platform designed to provide expanded manufacturing services to global pharmaceutical clients. |
| MedPharm | Jul-24 | MedPharm and Tergus Pharma announced a strategic merger, operating under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. The combined entity leverages enhanced scientific capabilities, clinical trial manufacturing, and commercial-scale production, including specialized facilities for hormone-based and highly potent drug development. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Semi-Solid Dosage CDMO Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Semi-Solid Dosage CDMO Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow big is the semi-solid dosage CDMO market?
What is the anticipated CAGR of the semi-solid dosage CDMO industry?
How is rising prevalence of skin disorders driving outsourcing demand in the semi-solid dosage CDMO market?
How are rising pharmaceutical R&D investments influencing semi-solid formulation complexity and CDMO demand?
Why does the Topical route dominate the semi-solid dosage CDMO market?
Why are biopharmaceutical companies the fastest-growing end-use segment in the semi-solid dosage CDMO market?
Why does North America lead the CDMO market?
How is Asia Pacific contributing to CDMO market growth?
Who are the major participants shaping the semi-solid dosage CDMO landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization